Bone Marrow Transplant is a condition where the Insured Person needs necessary medical treatment to replace malignant or defective bone marrow with normal bone marrow from healthy donors to stimulate the production of formed blood cells.
Bone Marrow Transplant. Adult Interventional Cardiology for Congenital Heart Defects Cardiac Laser Lead Removals Pulmonary Thromboendarterectomy Services Thoracoabdominal Aortic Aneurysm Repairs (TAA) Health Results (Wait Time Strategy): Schedule H Selected Cardiac Services Total Hip and Knee Joint Replacements (Primary 83 volumes) Cataract Surgeries Magnetic Resonance Imaging (MRI) Computed Tomography (CT) $571,200 Total Additional Base and One Time Funding $550,200 $765,000 Total Allocation $31,493,400 Allocations not provided in this schedule for 2010/11, will be provided to hospitals in subsequent planning cycles. Hospitals should assume, for planning purposes, funding for similar volumes for Priority Services in out-years. Global Volumes Schedule D1 2010/11 Hospital COLLINGWOOD General and Marine Fac # 640 2010/11 2010/11 Performance Performance Global Volumes Units of Service Target Standard** Total Acute Activity, including Weighted 4,900 4,410 - 5,390 inpatient and Day Surgery* Cases Other Complex Continuing Care RUG Weighted Patient Days Mental Health Inpatient Days ELDCAP Inpatient Days Rehabilitation Inpatient Days Emergency Department Visits Visits 31,483 >28,335 Ambulatory Care*** Visits 21,585 >16,189 * Global volumes based on CIHI Case mix Group (CMG)+ methodology and MOHLTC PAC-10 weights. ** Volume Performance Indicators under Global Volumes vary in application based on hospital type. ***Ambulatory Care includes OHRS Primary account codes 7134* (excluding 7134055), 712*, 7135*,715* OHRS secondary statistical account codes:447*,450*,5* (excluding 50*,511*,512*,513*,514*,518*,519*,521*) Performance Indicators Hospital COLLINGWOOD General and Marine Fac # 640 Performance Indicators HSAA Performance Indicators Perfomance Indicators For All Hospitals Current Ratio Year End Total Margin **Volume Performance Indicators under Global Volumes vary in application based on hospital type. 2010/11 2010/11 Performance Performance Target Standard** 0.68 0.8 - 2.0 0% 0% Once negotiated, an amendment will be made under section 15.3 of the Agreement to include these targets and any additional conditions not otherwise set out in Schedule B or B1. This funding would be an additional in-year allocation contemplated by section 5.3 of the Agreement Critical Care Funding Hospital This section has been intentionally left blank COLLINGWOOD General and Marine Schedule E1 2010/11 Once negotiated, an amendment (Sch F1.1) will be made under section 15.3 of the Agreement to include these target...
Bone Marrow Transplant as defined herein and specifically listed in the applicable chapter of the Florida Administrative Code or covered by Medicare as described in the most recently published Medicare Coverage Issues Manual issued by the Centers for Medicare and Medicaid Services. We will cover the expenses incurred for the donation of bone marrow by a donor to the same extent such expenses would be covered for you and will be subject to the same limitations and exclusions as would be applicable to you. Coverage for the reasonable expenses of searching for a donor will be limited to a search among immediate family members and donors identified through the National Bone Marrow Donor Program;
Bone Marrow Transplant in press. Xxxx XX, Xxxxxxxx ME, Xxxxxxx H, Xxxxxxxx JJ, Xxxxxxxxx F, Xxxxxx XX, Xxxxx WE. In children undergoing transplantation for non malignant disease, previous exposure to parental mesenchymal stromal cell infusions does not induce rejection of subsequent haploidentical hematopoietic stem cells. Submitted.
Bone Marrow Transplant c. Pre-hospitalization Medical Expenses or Post-hospitalization Medical Expenses of the organ donor.
Bone Marrow Transplant. Hematologic Disorders (one month) o The ambulatory care elective rotation in hematologic disorders / transplant specifically focuses on the treatment of patients with multiple myeloma, lymphomas, leukemia, non-malignant hematologic disorders and hematopoietic stem cell transplant. The specialty pharmacist in these clinic areas work in collaboration with the physicians, nurse clinicians, pharmacists (BCC satellite pharmacist, community pharmacist, inpatient pharmacists), medication access coordinators, and research coordinators in dosing, therapy choices, supportive care measures, chemotherapy, and acting as an educator/liaison between infusion nursing, pharmacy, and the inpatient Bone Marrow Transplant team. The resident will perform the same duties as the clinical pharmacy specialist and may serve as a preceptor to pharmacy students if on rotation concurrently. The resident is expected to attend clinic 4 days week. Longitudinal Rotations: (Throughout the year) • Ambulatory Care o Longitudinal ambulatory care rotation is a ten-month required learning experience for the PGY-2 oncology pharmacy resident. The practice area is located in the breast clinic for approximately four months and the other six months is split equally between lung clinic and gastrointestinal malignancy clinic. These clinics are located on the 2nd and 3rd floor of Brown Cancer Center. The specialty pharmacist in these clinics works in collaboration with the physicians, nurse clinicians, disease coordinators, and research coordinators. The pharmacist provides clinical support in decision making for drug dosing, therapy choices, supportive care measures, oral antineoplastic medications, and acts as an educator/liaison between infusion nursing, pharmacy, and the medical oncology team both on a patient case-by-case basis and when new standards of care for specific diseases or medications emerge. The pharmacy resident, under coaching and facilitation of the preceptor, will learn the role of a specialty pharmacist and provide care for outpatient oncology patients. The resident attends breast clinic one day of week for 4 months, gastrointestinal clinic and lung clinic each for 3 months throughout the residency year. • Service o Distributive: Resident(s) will learn to effectively staff the oncology satellite outpatient pharmacy. Responsibilities include preparing and dispensing oncology drugs and ancillary supportive medications according to facility requirements. The resident pharmacist will w...
Bone Marrow Transplant. The actual undergoing of a transplant of any of the below organ as a recipient or the inclusion on an official transplant waiting list for any of the below organ: - One of the following whole human organs: heart, lung, liver, kidney, pancreas or - Human bone marrow using haematopoietic stem cells preceded by total bone marrow ablation. The transplant must be medically necessary and based on objective confirmation of organ failure. Other than the above stem cell transplants are excluded. • Paralysis The total loss of function of two or more limbs due to injury or disease of the spinal cord or brain, where such functional loss is considered to be permanent by a neurologist. Loss of function of limbs classified as Diplegia, Tetraplegia and Quadriplegia are included. • Blindness Total irreversible loss of sight in both eyes as a result of illness or accident. The blindness must be certified by an ophthalmologist’s report. The blindness must not be able to be corrected by medical procedure.
Bone Marrow Transplant. Hematologic Disorders (one month) o The ambulatory care elective rotation in hematologic disorders / transplant specifically focuses on the treatment of patients with multiple myeloma, lymphomas, leukemia, non-malignant hematologic disorders and hematopoietic stem cell transplant. The specialty pharmacist in these clinic areas work in collaboration with the physicians, nurse clinicians, pharmacists (BCC satellite pharmacist, community pharmacist, inpatient pharmacists), medication access coordinators, and research coordinators in dosing, therapy choices, supportive care measures, chemotherapy, and acting as an educator/liaison between infusion nursing, pharmacy, and the inpatient Bone Marrow Transplant team. The resident will perform the same duties as the clinical pharmacy specialist and may serve as a preceptor to pharmacy students if on rotation concurrently. The resident is expected to attend clinic 4 days week. • Geriatrics (one month) o The geriatrics elective is a dedicated month of experience where the resident works with a multidisciplinary health care team in a variety of practice settings, including an ambulatory geriatric clinic, inpatient service and long term care. The goal of the rotation is to educate the resident on the care of the elderly and the pharmacist’s role in optimizing therapy to decrease medication related adverse events. The resident actively participates in patient care rounds and is expected to perform the same duties as the geriatric pharmacy specialist. • Multimodality (one month) o This multimodality elective rotation is a dedicated month of experience where the resident will collaborate with various healthcare teams to experience the oncology patients overall treatment plan. The healthcare teams include but not limited to radiation oncology, palliative care, surgery oncology, colorectal surgery, rehabilitation medicine, and interventional radiology. They will attend outpatient clinics and operating rooms as dictated by the discipline. While on palliative care, the resident will attend daily rounds and develop evidence based treatment plan with the team. • Clinical Infusion (one month) o Infusion- clinical elective rotation is a 1 month learning experience. The clinical infusion pharmacist will be a hybrid position with both clinical and staffing responsibilities. The pharmacist will work in collaboration with the staffing pharmacist, pharmacy technicians, nurses, physicians, and research coordinators in reviewing labs, pr...
Bone Marrow Transplant. Healthy bone marrow stem cells and the blood cells they create are crucial for survival, but certain diseases can affect the bone marrow, interfering with its ability to function properly. A bone marrow transplant is a process to replace unhealthy bone marrow with healthy bone marrow stem cells. Bone marrow transplant can save the lives of patients with blood cancers and genetic diseases and is a potential cure for patients with severe refractory autoimmune diseases. However, the high risks, toxic side effects and complexity of the procedure currently prevent many patients from being able to benefit. About Heidelberg Pharma Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. ATAC technology is the core activity of subsidiary Heidelberg Pharma Research GmbH. Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out-licensing and further development. The Company is listed on the Frankfurt Stock Exchange: ISIN DE000A11QW0 / WKN A11QW / Symbol WL6. More information is available at xxx.xxxxxxxxxx-xxxxxx.xxx. About Magenta Therapeutics Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients. Founded by internationally recognized leaders in bone marrow transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit xxx.xxxxxxxxx.xxx. Heidelberg Pharma AG Xxxxxx Xxxxxx Tel.: +00 00 00 00 00-00 Email: investors[at]xxxxxxxx.xxx Business Development Xx. Xxxxxx Xxxxxxx CBO, Executive Vice President Tel.: +00 0000 0000-00 Ema...
Bone Marrow Transplant. I. The actual undergoing of a transplant of:
